PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

AAIITO Expert Consensus Reframes Mild-to-Moderate Asthma Toward Proactive Control

Expert consensus on Management of Mild and Moderate AsthmaAAIITOmild-to-moderate asthmainhaled corticosteroidsICS/LABAbiomarkersFeNOeosinophils Pulmonology / Respiratory

Background Information

Expert consensus offers new guidelines for mild-to-moderate asthma management.

Mild and moderate asthma often remain poorly controlled, leading to exacerbations and limitations in daily activities. Consensus on asthma management includes optimal control without symptoms and exacerbations, using personalized treatment and patient education. These consensus guidelines provide practical recommendations validated for clinical appropriateness to improve asthma management and control. A proactive, patient-centric approach is key to managing mild-to-moderate asthma effectively.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Martini M, Cecchi L, Musarra A, Jaubashi K, Marra AM, Murzilli F, Papia F, Valenti G, Yang B, Cazzola M, Vaghi A, Bilò MB

Citation: Martini M, Cecchi L, Musarra A, et al. Expert consensus on the management of mild and moderate asthma. Respiratory medicine. 2026;262:109078. doi:10.1016/j.rmed.2026.109078

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.